AI assistant
ADALTA LIMITED — Share Issue/Capital Change 2020
Nov 8, 2020
64247_rns_2020-11-08_7af703d9-7099-40ad-8087-dc16a980fd14.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
==> picture [539 x 74] intentionally omitted <==
9 November 2020
ASX Announcement
NOTIFICATION OF EXPIRED OPTIONS
MELBOURNE Australia, 9 November 2020: AdAlta Limited (ASX:1AD), advises a total of 834,472 unlisted options have expired. Details of the expired options are outlined below.
| Details | Number | Exercise Price |
Expiry Date | ASX Code |
|---|---|---|---|---|
| Unlisted options | 600,000 | $0.1685 | 16 October 2020 | 1ADAD |
| Unlisted options | 234,472 | $0.1685 | 1 November 2020 | 1ADAD |
Set out below is an updated capital structure of the Company following the expiry of options.
options. |
||||
|---|---|---|---|---|
| Details | Number | Exercise Price |
Expiry Date | ASX Code |
| Ordinary Shares | 245,175,853 | N/A | N/A | 1AD |
| Listed options | 23,348,803 | $0.2485 | 30/06/2021 | 1ADO |
| Unlisted options | 400,000 | $0.2485 | 14/11/2021 | 1ADAD |
| Unlisted options | 130,000 | $0.4985 | 14/11/2021 | 1ADAD |
| Unlisted options | 100,000 | $0.7485 | 14/11/2021 | 1ADAD |
| Unlisted options | 100,000 | $0.9985 | 14/11/2021 | 1ADAD |
| Unlisted options | 620,535 | $0.2385 | 27/02/2022 | 1ADAD |
| Unlisted options | 4,929,060 | $0.2485 | 26/11/2025 | 1ADAD |
| Unlisted options | 600,000 | $0.0835 | 20/03/2023 | 1ADAE |
Authorised for lodgement by:
Tim Oldham CEO and Managing Director November 2020
==> picture [595 x 83] intentionally omitted <==
==> picture [539 x 74] intentionally omitted <==
Notes to Editors About AdAlta
AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen-binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.
AdAlta is conducting a Phase 1 clinical trial for its lead i-body candidate, AD-214. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high unmet medical need.
The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with multi-national company GE Healthcare for discovery of a diagnostic imaging agent against Granzyme B for use in immunooncology.
AdAlta’s strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.
Further information can be found at: https://adalta.com.au
For more information, please contact:
Investors
Media
Tim Oldham, CEO & Managing Director IR Department Tel: +61 403 446 665 Tel: +61 411 364 382 E: [email protected] E: [email protected]
==> picture [595 x 83] intentionally omitted <==